Abstracts tagged "axial spondyloarthritis"

Abstract Number: 2777 • 2019 ACR/ARP Annual Meeting
What Is Axial Spondyloarthritis? A Latent Class and Transition Analysis in the SPACE and DESIR Cohorts
Alexandre Sepriano¹, Sofia Ramiro ², Désirée van der Heijde ¹, Pierre Hoonhout ³, Anna Moltó ⁴, Alain Saraux ⁵, Maxime Dougados ⁶ and Robert B.M. Landewé ⁷, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands, ³ISEG - Lisbon School of Economics and Management, Lisbon, Portugal, ⁴Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, ⁵CHU de la Cavale-Blanche Brest, Brest, France, ⁶Cochin Hospital, Paris, France, ⁷Amsterdam University Medical Center, Amsterdam, Netherlands
Background/Purpose: Axial spondyloarthritis (axSpA) is a disease with a rather heterogeneous presentation that may be difficult to diagnose. Classification criteria, such as the ASAS criteria,…
Abstract Number: 568 • 2019 ACR/ARP Annual Meeting
Understanding mNY Radiograph Score Discordance in Axial Spondyloarthritis Clinical Trials Using Imaging Criteria for Subject Eligibility
Farhan Syed¹, Kassel Fotinos-Hoyer ², Michael O'Connor ³, Maureen Li ³, Bryan Hermannsson ², Nicholas Enus ³, Sayali Karve ³, Manish Sharma ⁴, Gabriele Pradella ³, Robert B.M. Landewé ⁵, Xenofon Baraliakos ⁶ and Sarah Warner ³, ¹Parexel, Billerica, MA, ²Parexel, Berlin, Germany, ³Parexel, Billerica, ⁴Parexel, Hyderabad, India, ⁵Amsterdam University Medical Center, Amsterdam, Netherlands, ⁶Rheumatology Department, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is typically radiographically confirmed on the sacroiliac joint (SIJ) as assessed by the modified New York (mNY) criteria. In clinical trials,…
Abstract Number: 606 • 2019 ACR/ARP Annual Meeting
Effectiveness of TNFi After a First Switch in Patients with Early Axial Spondyloarthritis: A Longitudinal Analysis of the DESIR Cohort
Marion Pons ¹, Sylvie Chevret ², Karine Briot ³, Maria-Antonietta D’Agostino ⁴, Christian Roux ⁵, Maxime Dougados ⁶ and Anna Moltó⁵, ¹Rheumatology department, Cochin Hospital, Paris, Paris, Ile-de-France, France, ²INSERM U-1153, CRESS Paris-Sorbonne, Paris, Paris, Ile-de-France, France, ³Rheumatology department, Cochin Hospital, Paris, France, Paris, Ile-de-France, France, ⁴Department of Rheumatology, APHP, Hôpital Ambroise Paré, Paris, France, ⁵Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, ⁶Cochin Hospital, Paris, France
Background/Purpose: Contradictory data has been reported on the effectiveness of a second and third line of TNFi in early axial spondyloarthritis (axSpA). The objective of…
Abstract Number: 851 • 2019 ACR/ARP Annual Meeting
Association Between Bone Marrow Edema and Structural Progression in the Same Quadrant in Axial Spondyloarthritis – 5-year Data from the DESIR Cohort
Santiago Rodrigues-Manica¹, Alexandre Sepriano ², Sofia Ramiro ³, Robert B.M. Landewé ⁴, Pascal Claudepierre ⁵, Anna Molto ⁶, Maxime Dougados ⁷, Miranda van Lunteren ² and Désirée van der Heijde ², ¹CEDOC, NOVA-Medical School | Hospital Egas Moniz, CHLO, Lisbon, Lisbon, Portugal, ²Leiden University Medical Center, Leiden, Netherlands, ³Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands, ⁴Amsterdam University Medical Center, Amsterdam, Netherlands, ⁵Rheumatology, CHU Henri Mondor Créteil, Paris, France, ⁶Paris Descartes University, Medicine Faculty; APHP, Rheumatology, Hôpital Cochin, Hôpitaux de Paris, Paris, Paris, France, ⁷Cochin Hospital, Paris, France
Background/Purpose: The overall presence of inflammation in the MRI-SIJ is associated with overall 5-year radiographic damage in patients with axSpA. But we do not know…
Abstract Number: 1491 • 2019 ACR/ARP Annual Meeting
Long-term Clinical Outcome of Anti-TNF Treatment in Patients with Early Axial Spondyloarthritis: 10-year Data of the Etanercept vs. Sulfasalazin in Early Axial Spondyloarthritis Trial
Fabian Proft¹, Murat Torgutalp ², Anja Weiß ³, Mikhail Protopopov ⁴, Valeria Rios Rodriguez ⁵, Hildrun Haibel ¹, Olaf Behmer ⁶, Joachim Sieper ¹ and Denis Poddubnyy ⁷, ¹Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Germany and Ankara University Faculty of Medicine, Ankara, Turkey., Berlin, Germany, ³German Rheumatism Research Center (DRFZ), Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Germany, Berlin, Berlin, Germany, ⁵Charité Universitätsmedizin, Berlin, Germany, ⁶Pfizer Inc., Berlin, Germany, ⁷Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany
Background/Purpose: Long-term data on anti-TNF treatment in patients with early axial spondyloarthritis (SpA) is scarce. The objective of this analysis was to assess the long-term…
Abstract Number: 1549 • 2019 ACR/ARP Annual Meeting
Primary 1-Year Data of Ixekizumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Patients with Radiographic Axial Spondyloarthritis Including Data in Patients Rerandomized from Adalimumab to Ixekizumab
Cheng-Chung Wei¹, Lianne Gensler ², Jessica Walsh ³, Robert B.M. Landewé ⁴, Tetsuya Tomita ⁵, Fangyi Zhao ⁶, Gaia Gallo ⁶, Hilde Carlier ⁷ and Maxime Dougados ⁸, ¹Chung Shan Medical University, Taichung City, Taiwan (Republic of China), ²University San Francisco California, San Francisco, CA, ³Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁴Amsterdam University Medical Center, Amsterdam, Netherlands, ⁵Osaka University Graduate School of Medicine, Osaka, Japan, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Eli Lilly and Company, Indianapolis, ⁸Hôpital Cochin, Paris, France
Background/Purpose: During 16 weeks of blinded treatment, ixekizumab (IXE) and an adalimumab (ADA) active reference arm were found superior to placebo (PBO) in improving signs…
Abstract Number: 2778 • 2019 ACR/ARP Annual Meeting
Alcohol Consumption as a Predictor of the Progression of Spinal Structural Damage in Axial Spondyloarthritis: Data from the Catholic Axial Spondyloarthritis COhort (CASCO)
Hong Ki Min¹, Seung-Ki Kwok ² and Sang-Heon Lee ¹, ¹Konkuk university medical center, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
Background/Purpose: The purpose of the present study was to demonstrate the predicting factors of spinal structural damage in axial spondyloarthritis (axSpA) in a prospective cohort…
Abstract Number: 573 • 2019 ACR/ARP Annual Meeting
Identification of Factors Associated with Magnetic Resonance Images Changes Suggestive of Axial Spondyloarthritis in the Axial Skeleton of Individuals < 45 Years – Evaluation of Data from a Large Community Study
Xenofon Baraliakos¹, Adrian Richter ², Daniel Feldmann ³, Anne Ott ³, Robin Buelow ⁴, Carsten Oliver Schmidt ⁵ and Jürgen Braun ⁶, ¹Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ²Institute for Community Medicine, University Greifswald, and German Rheumatism Research Center, Berlin, Berlin, Germany, ³Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ⁴Department of Diagnostic Radiology and Neuroradiology, University Medicine Greifswald, Greifswald, Germany, ⁵Institute for Community Medicine, University Greifswald, Greifswald, Germany, ⁶Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany
Background/Purpose: Active (bone marrow edema, BME) and structural (fatty lesions, FL) lesions in the spinal and the sacroiliac joints (SIJ), as assessed by magnetic resonance…
Abstract Number: 607 • 2019 ACR/ARP Annual Meeting
Expansion of Peripheral Cytotoxic T Cells in Co-morbid Inflammatory Bowel Disease and Spondyloarthritis
Adam Lefferts¹, Emilie Regner ², Andrew Stahly ³, Rebecca O'Rourke ¹, Kenneth Jones ² and Kristine Kuhn ¹, ¹University of Colorado, Anschutz Medical Campus, Aurora, CO, ²University of Colorado, Anschutz Medical Campus, Denver, CO, ³University of Colorado, Aurora, CO
Background/Purpose: Background: The clinical overlap of axial spondyloarthritis (axSpA) and Crohn’s disease (CD) has given rise to the hypothesis that these conditions may share pathophysiologic…
Abstract Number: 854 • 2019 ACR/ARP Annual Meeting
Do Smoking and Socio-economic Factors Independently Influence Imaging Outcomes in Axial Spondyloarthritis? Five-year Data from the DESIR Cohort
Elena Nikiphorou¹, Sofia Ramiro ², Alexandre Sepriano ³, Adeline Ruyssen Witrand ⁴, Robert B.M. Landewé ⁵ and Désirée van der Heijde ³, ¹King's College London, London, United Kingdom, ²Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology center, Pierre Paul Riquet Hospital, CHU of Toulouse, Paul Sabatier University, UMR 1027, Inserm, France, Toulouse, France, ⁵Amsterdam University Medical Center, Amsterdam, Netherlands
Background/Purpose: Smoking and systemic inflammation have been shown to independently associate with radiographic spinal progression in patients with axSpA. Evidence suggests that certain socioeconomic (SE)…
Abstract Number: 1492 • 2019 ACR/ARP Annual Meeting
Exposure-Response Analyses for Upadacitinib Efficacy and Safety in Ankylosing Spondylitis – Analyses of the SELECT-AXIS I Study
Mohamed Ismail¹, Ahmed Nader ¹, Insa Winzenborg ², In-Ho Song ³ and Ahmed Othman ¹, ¹AbbVie Inc., North Chicago, IL, ²AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany, ³AbbVie Inc., North Chicago, IL, USA, North Chicago, IL
Background/Purpose: Upadacitinib, a selective inhibitor of Janus kinase 1 (JAK1), is currently being evaluated for the treatment of several autoimmune disorders, including axial spondyloarthritis (axial…
Abstract Number: 1551 • 2019 ACR/ARP Annual Meeting
Does Retention and Remission Rates to 2nd and 3rd TNF Inhibitors in Patients with Axial Spondyloarthritis Depend on the Reason from Withdrawal to the Previous Treatment? – Real World Data from 12 European Countries in the EuroSpA Research Collaboration
Lykke Midtbøll Ørnbjerg ¹, Cecilie Heegaard Brahe¹, Anne Gitte Loft ², Johan Askling ³, Adrian Ciurea ⁴, Herman Mann ⁵, Servet Akar ⁶, Eirik Kristianslund ⁷, Dan Nordström ⁸, Maria José Santos ⁹, Catalin Codreanu ¹⁰, Manuel Pombo-Suarez ¹¹, Ziga Rotar ¹², Bjorn Gudbjornsson ¹³, Daniela DiGuiseppe ¹⁴, Michael J. Nissen ¹⁵, Karel Pavelka ⁵, Soner Senel ¹⁶, Joe Sexton ¹⁷, Kari K. Eklund ¹⁸, Anabela Barcelos ¹⁹, Ruxandra IONESCU ²⁰, Carlos Sánchez-Piedra ²¹, Matija Tomsic ²², Arni Jon Geirsson ²³, Irene van der Horst-Bruinsma ²⁴, Gary Macfarlane ²⁵, Florenzo Iannone ²⁶, Brigitte Michelsen ¹, Lise Hyldstrup ²⁷, Niels Steen Krogh ²⁸, Merete Lund Hetland ²⁹ and Mikkel Østergaard ³⁰, ¹EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark, ²Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, ³Karolinska Institutet, Stockholm, Sweden, ⁴University Hospital Zürich, Zürich, Switzerland, ⁵Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁶Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, ⁷Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ⁸Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, ⁹Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ¹⁰Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹¹Rheumatology Unit, Clinical University Hospital of Santiago de Compostela,, Santiago, Spain, ¹²UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ¹³Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹⁴Clinical Epidemiology Division, Dept of Medicine Solna, Karolinska Institutet,, Stockholm, Sweden, ¹⁵University Hospital Geneva, Geneva, Switzerland, ¹⁶Division of Rheumatology, Erciyes University School of Medicine, Kayseri, Turkey, Kayseri, Turkey, ¹⁷Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ¹⁸ROB-FIN registry, Department of Medicine, Helsinki University and University Hospital, Helsinki, Finland, ¹⁹Centro Hospitalar Baixo Vouga | iBemed, University of Aveiro, Aveiro, Portugal, ²⁰SPITALUL CLINIC SFANTA MARIA, Bucharest, ²¹Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ²²Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, ²³Centre for Rheumatology Research, University Hospital and Faculty of Medicine, Reykjavik, Iceland, ²⁴Amsterdam University Medical Center, Amsterdam, Netherlands, ²⁵University of Aberdeen, Aberdeen, United Kingdom, ²⁶Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ²⁷Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, ²⁸Zitelab / DANBIO, Copenhagen, Denmark, ²⁹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ³⁰Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Tumour necrosis factor inhibitors (TNFi) are efficacious in patients with axial spondyloarthritis (axSpA), but still some patients switch to a different TNFi because of…
Abstract Number: 2779 • 2019 ACR/ARP Annual Meeting
Higher Disease Activity Is Associated with More Spinal Radiographic Progression in Patients with Axial Spondyloarthritis Independently of Prior Exposure to TNF Inhibitors
Alexandre Sepriano¹, Sofia Ramiro ², Stephanie Wichuk ³, Praveena Chiowchanwisawakit ⁴, Terrie MacCosham ³, Joel Paschke ⁵, Désirée van der Heijde ¹, Robert B.M. Landewé ⁶ and Walter Maksymowych ⁷, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands, ³University of Alberta, Edmonton, Canada, ⁴Mahidol University, Bangkok, Thailand, ⁵CARE Arthritis, Edmonton, Canada, ⁶Amsterdam University Medical Center, Amsterdam, Netherlands, ⁷University of Alberta and CARE Arthritis, Edmonton, Canada
Background/Purpose: The association between disease activity and spinal radiographic progression in radiographic axial spondyloarthritis (r-axSpA) has been previously shown in a cohort of patients (pts)…
Abstract Number: 577 • 2019 ACR/ARP Annual Meeting
Gender Contrasts in Patient Reported Outcomes Don’t Alter the Disease Activity Score in Axial Spondyloarthritis Patients
Ann-Sophie De Craemer¹, Thomas Renson ¹, Liselotte Deroo ¹, Manouk de Hooge ¹, Philippe Carron ¹, Filip Van den Bosch ¹ and Dirk Elewaut ¹, ¹Ghent University Hospital, Ghent, Belgium
Background/Purpose: Disease activity in axial spondyloarthritis (axSpA) is often quantified by the Ankylosing Spondylitis Disease Activity Score (ASDAS), a composite index which combines 4 patient…
Abstract Number: 608 • 2019 ACR/ARP Annual Meeting
Prevalence of Radiographic Entheseal Lesions at the Hip and Pelvic Region in Patients with Ankylosing Spondylitis versus Controls
Freke Wink¹, Thomas Diemel ², Suzanne Arends ² and Anneke Spoorenberg ², ¹Medical Center Leeuwarden, Leeuwarden, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Enthesitis is one of the features of ankylosing spondylitis (AS). High prevalence of structural and inflammatory ultrasound lesions of peripheral entheses are found in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].